Mankind Pharma Ltd. · NSE:MANKIND
Mankind Pharma — Q2 FY27 Earnings Presentation
26 slides from Mankind Pharma's earnings presentation, Oct 26, 2026
Slide 1: Exchange filing cover letter: Investor Presentation
October 26, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Investor Presentation Ref: Regulation 30 of t
Slide 2: Investor Presentation Q2 & H1 FY27
ig Mankindil> INVESTOR PRESENTATION Q2 & HIFY27 October 2026
Slide 3: Index
Index 03 Additional Information • Mankind Pharma at a Glance (FY26) • Key Milestones • Expansion in Specialty and Super Specialty Segments 01 Financial Performance • Financials - Steady Growth Trajectory • Key Financials – Q2 FY27 • Shareholding Pattern • P & L Highlights – Q2 & H1 FY27 • Annexures
Slide 4: Financial Performance
ig Mankindii> Sirois Life Financial Performance
Slide 5: Revenue grew ~17% YoY with EBITDA margins improving by 210 bps
Mr. Rajeev Juneja Vice Chairman & Managing Director Segmental Revenue Break - Up • Revenue grew ~17% YoY with EBITDA margins improving by 210 bps to 27.1% • Strong domestic business3 growth of 15.9% led by 1.2x volume outperformance to IPM, further supported by: 16% 6% Mid-teen growth in Mankind D
Slide 6: P&L Highlights – Q2 & H1 FY27
YoY QoQ YoY INR Cr Q2 FY27 Q2FY26 Q1FY27 H1 FY27 H1 FY26 Growth Growth Growth Revenue from Operations 4,338 3,697 17.3% 4,031 7.6% 8,368 7,268 15.1% (A=B+C) Domestic Business (B) 3,657 3,184 14.8% 3,426 6.7% 7,082 6,285 12.7% i. Domestic Business (ex CH) 3,428 2,958 15.9% 3,180 7.8% 6,608 5,822 13.5
Slide 7: Cash flow, capex, ROCE, working capital and net cash
Cash Flow from Operations (INR Cr) CAPEX (INR Cr) ROCE2 CFO to CAPEX as % 80% 89% 92% 81% 4.3% 5.2% 4.0% 4.9% EBITDA of Rev With BSV With BSV With BSV With BSV Acquisition Acquisition Acquisition Acquisition 723 263 45% 40% 41% 41% 814 761 187 184 460 797 797 1,002 91 214 593 128 163 163 546 840 840
Slide 8: Business Updates
ig Mankindil> Jeroing Life Business Updates
Slide 9: Strong Growth in Domestic (ex-CH) Revenue
Strong Growth in Domestic (ex-CH) Revenue1 INR Cr 11,338 9,866 8,741 3,428 2,958 FY24 FY25 FY26 Q2FY26 Q2FY27 Domestic revenue (ex- CH) increased 15.9% YoY driven by strong double digit growth in both Mankind and BSV specialty business Secondary sales2 growth of 15.7% vs 14.2% IPM4 in Q2FY27 ind
Slide 10: Outperformance to IPM in Cardiac and Anti-Diabetic; chronic focus
Consistent focus to increase chronic contribution Overall Chronic Growth 1.3x 1.2x 1.1x2 1.4x2 1.1x2 40.4 39.8 17.2 17.9 39.0 39.0 38.3 40.12 38.5 14.3 39.02 37.4 12.7 13.7 13.4 38.52 36.6 11.8 11.8 16.12 36.6 9.9 9.7 12.42 35.2 10.52 FY24 FY25 FY26 Q2 FY26 3 Q2 FY27 FY24 FY25 FY26 Q2FY26 Q2FY27 IPM
Slide 11: Key new launches gaining strong traction
Brand Families Sales CAGR FY 21 FY 26 MAT Sep’26 Sales (FY21-26) > INR 500 Crore 0 3 3 14.4% > INR 200 Crore 7 13 14 12.8% > INR 100 Crore 15 22 26 12.3% > INR 50 Crore 36 54 63 11.2% Key new launches gaining strong traction - Vonalong, Empagreat, Dynaduo, Nurokind HS PFS and Pantakind Raft As per I
Slide 12: High Ranks across Acute and Chronic Areas
High Ranks across Acute and Chronic Areas FY26 - Sales Mix representing Diversified Therapy Presence Rank in CVM MS% FY 21-26 CAGR Key Therapy Areas 2% (FY26) (FY26) 11% Mankind1 IPM 17% Cardiovascular Anti-Infectives Chronic therapies 3 4.3% 14.3% 11.4% 4% Gynaecology Gastro Intestinal Cardiovascul
Slide 13: Consumer Healthcare Segment Revenue
Consumer Healthcare Segment Revenue (INR Cr) EBITDA % 19.9% 19.0% 18.7%1 18.0% 19.1% 879 809 706 1.2% 226 229 FY24 FY25 FY26 Q2FY26 Q2FY27 Revenue growth impacted by slower offtake in category for the industry and some regional impact in East and South Despite softer growth, we gained market sha
Slide 14: Strategically selected national and regional brand ambassadors
Strategically selected national and regional brand ambassadors Corporate Brand Ambassadors Dominant Brands Consumer Healthcare Brand Ambassadors #1 Condom Brand Sunny Manasvi Leone Mamgai Market Share – 29% #1 Anushka Kajal Srabanti Pregnancy Test Kit Brand Sharma Aggarwal Chatterjee Market Share –
Slide 15: Revenue from Exports
Revenue from Exports (INR Cr) 1 2,061 1,532 813 681 513 FY24 FY25 FY26 Q2FY26 Q2FY27 International revenue increased by 33% in Q2FY27 driven by strong growth in both Mankind and BSV International Mankind has launched 1 new product in Q2FY27 taking the total launched products to 50 in US 1. Denot
Slide 16: ESG: Organization Focus on Sustainable Growth FY27 (H1)
ESG : Organization Focus on Sustainable Growth FY27 (H-1) Zero Reportable Lost Time Key Key Key Adoption of accidents across all Highlights Initiatives Priorities Technologies manufacturing units • Annual FY26 BRSR-compliant • Energy Audit at BSV- • Sustainability assessment for all • Advanced waste
Slide 17: Additional Information
ig Mankindii> Serving Life y/ Additional Information
Slide 18: Mankind Pharma at a Glance (FY26)
Rank in Prescriptions over Rank by volume in Rank by value in IPM1 / Consumer Healthcare brands Market the last nine years1 IPM1 Gynaecology ranked #1 in their categories1 Leadership Brand families1 worth FY26 Revenue FY26 Domestic Revenue Mar’26 Field force2 INR 50/100 Cr+ Scale Revenue CAGR FY21-2
Slide 19: Key Milestones
1995 2004 2007-10 2018-19 2020-21 2022 2023 2024 2025-26 Entered into in-licensing Acquired agreements with: 100% stake in Successfully listed BSV Limited Commenced Entered chronic Entered Acquired brands 1. Astra Zeneca - Paonta Sahib on NSE and BSE 1. Acquired Rivotril operation in 1995 pharmaceut
Slide 20: Expansion in Specialty and Super Specialty Segments
Mass Market Specialty Chronic (Acute/ Chronic / Semi Chronic) (Cardio / Diabeto / CNS) Consumer Healthcare (OTC) BSV - Super Specialty Targeted Medical Practitioners Targeted Medical Practitioners Targeted Medical Practitioners GP CP MD MD DM KOL GT MT ECOM MD DM KOL INR 11,338 Cr 28%/ 39% ~INR 879
Slide 21: Financials - Steady Growth Trajectory
Revenue (INR Cr) Strong Growth in Domestic Revenue (INR Cr) 16% 13% CAGR CAGR 14,278 12,207 12,217 10,260 10,675 8,749 9,447 7,782 8,453 7,595 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 EBITDA (INR Cr) and Margin % (2) 25.8% 21.9% 24.6% 25.9%3 25.4%4 3,629 4 3 3,159 2,529 2,004 1,913 FY22 FY2
Slide 22: Shareholding Pattern
BSE Ticker 543904 1.3% 1.8% 13.8% NSE Symbol MANKIND # of Shares outstanding1 41,30,45,090 10.5% Share Price2 2,503.80 Market Cap. (INR Cr)1 1,03,418 72.6% % Free Float3 26.4% Free Float Market Cap. (INR Cr) 27,302 Promoters & Promoter Group FPI & Bodies Corporate Mutual Funds Retail Industry Pharma
Slide 23: Annexures: formulas and definitions
• ROCE = (EBIT for the year ) / (Capital employed less cash) o EBIT excludes other income o Capital employed is the sum of total equity, total borrowings, total lease liabilities and deferred tax liabilities (net) less deferred tax assets and Cash. • Adjusted ROCE = (Adjusted EBIT for the year )/ (A
Slide 24: Q2 & H1 FY27 Earnings Call Details
Date 26th October, 2026 Time 05:00 PM – 06:00 PM IST Link Zoom Call https://us06web.zoom.us/webinar/register/WN_anw4QZ4XSYCYhCIJEERezA 23
Slide 25: Disclaimer
The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “would”, “will continue”, “contemplate” “intends”, “plans”, “estimates”, “seek to”, “future”, “objective”, “projects”, “goal”, “likely”, “project”
Slide 26: Thank You
Thank You For more information please visit our website: https://www.mankindpharma.com For specific queries, contact: Prakash Agarwal President Strategy 011 – 46846700 Ext. 3532 Investor.relations@mankindpharma.com